UB Paderborn / Katalog / Suche / in CDI

Principles and applicability of CSF sampling for the assessment of CNS drug delivery and pharmacodynamics

Advanced drug delivery reviews, 2004-10, Vol.56 (12), p.1825-1857

2004

Volltextzugriff (PDF)

Passive permeability and P-glycoprotein-mediated efflux differentiate central nervous system (CNS) and non-CNS marketed drugs

The Journal of pharmacology and experimental therapeutics, 2002-12, Vol.303 (3), p.1029

2002

Volltextzugriff (PDF)

PhRMA CPCDC initiative on predictive models of human pharmacokinetics, part 3: Comparative assessement of prediction methods of human clearance

Journal of pharmaceutical sciences, 2011-10, Vol.100 (10), p.4090-4110

2011

Volltextzugriff (PDF)

Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of GSK2336805, an Inhibitor of Hepatitis C Virus (HCV) NS5A, in Healthy Subjects and Subjects Chronically Infected with HCV Genotype 1

Antimicrobial Agents and Chemotherapy, 2013-10, Vol.57 (10), p.5037-5044

2013

Volltextzugriff (PDF)

PHRMA CPCDC initiative on predictive models of human pharmacokinetics, part 5: Prediction of plasma concentration–time profiles in human by using the physiologically‐based pharmacokinetic modeling approach

Journal of pharmaceutical sciences, 2011-10, Vol.100 (10), p.4127-4157

2011

Volltextzugriff (PDF)

Hepatotoxicity Observed in Clinical Trials of Aplaviroc (GW873140)

Antimicrobial Agents and Chemotherapy, 2008-03, Vol.52 (3), p.858-865

2008

Volltextzugriff (PDF)

Echocardiogram Study To Evaluate the Effect of the Novel Hepatitis C Virus NS5A Inhibitor GSK2336805 on Cardiac Contractility in Healthy Subjects

Antimicrobial Agents and Chemotherapy, 2013-10, Vol.57 (10), p.5141-5143

2013

Volltextzugriff (PDF)

PhRMA CPCDC initiative on predictive models of human pharmacokinetics, part 4: Prediction of plasma concentration–time profiles in human from in vivo preclinical data by using the Wajima approach

Journal of pharmaceutical sciences, 2011-10, Vol.100 (10), p.4111-4126

2011

Volltextzugriff (PDF)

Pharmacokinetics of Antiretroviral Drug Varies With Formulation in the Target Population of Children With HIV-1

Clinical pharmacology and therapeutics, 2012-02, Vol.91 (2), p.272-280

2012

Volltextzugriff (PDF)

Oral Sulfasalazine as a Clinical BCRP Probe Substrate: Pharmacokinetic Effects of Genetic Variation (C421A) and Pantoprazole Coadministration

Journal of pharmaceutical sciences, 2010-02, Vol.99 (2), p.1046-1062

2010

Volltextzugriff (PDF)

Pharmacokinetic and pharmacokinetic/pharmacodynamic characterization of the dolutegravir/rilpivirine two‐drug regimen in SWORD‐1/‐2 phase 3 studies

British journal of clinical pharmacology, 2023-07, Vol.89 (7), p.2190-2200

2023

Volltextzugriff (PDF)

Development of Dolutegravir Single-entity and Fixed-dose Combination Formulations for Children

The Pediatric infectious disease journal, 2022-03, Vol.41 (3), p.230

2022

Volltextzugriff (PDF)

PhRMA CPCDC initiative on predictive models of human pharmacokinetics, part 2: Comparative assessment of prediction methods of human volume of distribution

Journal of pharmaceutical sciences, 2011-10, Vol.100 (10), p.4074-4089

2011

Volltextzugriff (PDF)

Simultaneous Pharmacokinetic Screening of a Mixture of Compounds in the Dog Using API LC/MS/MS Analysis for Increased Throughput

Journal of medicinal chemistry, 1997-03, Vol.40 (6), p.827-829

1997

Volltextzugriff (PDF)

Pharmacokinetics and Short-Term Safety of 873140, a Novel CCR5 Antagonist, in Healthy Adult Subjects

Antimicrobial Agents and Chemotherapy, 2005-07, Vol.49 (7), p.2802-2806

2005

Volltextzugriff (PDF)

Biarylaniline Phenethanolamines as Potent and Selective β3 Adrenergic Receptor Agonists

Journal of medicinal chemistry, 2006-05, Vol.49 (9), p.2758-2771

2006

Volltextzugriff (PDF)

Antiviral activity and safety of aplaviroc, a CCR5 antagonist, in combination with lopinavir/ritonavir in HIV‐infected, therapy‐naïve patients: results of the EPIC study (CCR100136)

HIV medicine, 2009-02, Vol.10 (2), p.116-124

2009

Volltextzugriff (PDF)

PhRMA CPCDC Initiative on Predictive Models of Human Pharmacokinetics, Part 1: Goals, Properties of the Phrma Dataset, and Comparison with Literature Datasets

Journal of pharmaceutical sciences, 2011-10, Vol.100 (10), p.4050-4073

2011

Volltextzugriff (PDF)

Use of “N-in-one” Dosing to Create an in Vivo Pharmacokinetics Database for use in Developing Structure—Pharmacokinetic Relationships

Journal of pharmaceutical sciences, 1999-03, Vol.88 (3), p.313-318

1999

Volltextzugriff (PDF)

Pharmacokinetics of hepatitis C virus NS5A inhibitor JNJ-56914845 (GSK2336805) in subjects with hepatic impairment

Journal of clinical pharmacology, 2015-09, Vol.55 (9), p.1042-1050

2015

Volltextzugriff (PDF)

Evaluation of the Drug Interaction Potential of Aplaviroc, a Novel Human Immunodeficiency Virus Entry Inhibitor, Using a Modified Cooperstown 5 + 1 Cocktail

Journal of clinical pharmacology, 2006-05, Vol.46 (5), p.577-587

2006

Volltextzugriff (PDF)

Steady-state brain concentrations of antihistamines in rats: interplay of membrane permeability, P-glycoprotein efflux and plasma protein binding

Pharmacology, 2004-10, Vol.72 (2), p.92-98

2004

Volltextzugriff (PDF)

Monitoring liver safety in drug development: The GSK experience

Regulatory toxicology and pharmacology, 2007-11, Vol.49 (2), p.90-100

2007

Volltextzugriff (PDF)

The ABCG2 C421A polymorphism does not affect oral nitrofurantoin pharmacokinetics in healthy Chinese male subjects

British journal of clinical pharmacology, 2008-08, Vol.66 (2), p.233-239

2008

Volltextzugriff (PDF)

Semicarbazone-based inhibitors of cathepsin K, are they prodrugs for aldehyde inhibitors?

Bioorganic & medicinal chemistry letters, 2006-02, Vol.16 (4), p.978-983

2006

Volltextzugriff (PDF)

Menü

Weitere Dienste

Einstellungen

Principles and applicability of CSF sampling for the assessment of CNS drug delivery and pharmacodynamics

Passive permeability and P-glycoprotein-mediated efflux differentiate central nervous system (CNS) and non-CNS marketed drugs

PhRMA CPCDC initiative on predictive models of human pharmacokinetics, part 3: Comparative assessement of prediction methods of human clearance

Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of GSK2336805, an Inhibitor of Hepatitis C Virus (HCV) NS5A, in Healthy Subjects and Subjects Chronically Infected with HCV Genotype 1

PHRMA CPCDC initiative on predictive models of human pharmacokinetics, part 5: Prediction of plasma concentration–time profiles in human by using the physiologically‐based pharmacokinetic modeling approach

Hepatotoxicity Observed in Clinical Trials of Aplaviroc (GW873140)

Echocardiogram Study To Evaluate the Effect of the Novel Hepatitis C Virus NS5A Inhibitor GSK2336805 on Cardiac Contractility in Healthy Subjects

PhRMA CPCDC initiative on predictive models of human pharmacokinetics, part 4: Prediction of plasma concentration–time profiles in human from in vivo preclinical data by using the Wajima approach

Pharmacokinetics of Antiretroviral Drug Varies With Formulation in the Target Population of Children With HIV-1

Oral Sulfasalazine as a Clinical BCRP Probe Substrate: Pharmacokinetic Effects of Genetic Variation (C421A) and Pantoprazole Coadministration

Pharmacokinetic and pharmacokinetic/pharmacodynamic characterization of the dolutegravir/rilpivirine two‐drug regimen in SWORD‐1/‐2 phase 3 studies

Development of Dolutegravir Single-entity and Fixed-dose Combination Formulations for Children

PhRMA CPCDC initiative on predictive models of human pharmacokinetics, part 2: Comparative assessment of prediction methods of human volume of distribution

Simultaneous Pharmacokinetic Screening of a Mixture of Compounds in the Dog Using API LC/MS/MS Analysis for Increased Throughput

Pharmacokinetics and Short-Term Safety of 873140, a Novel CCR5 Antagonist, in Healthy Adult Subjects

Biarylaniline Phenethanolamines as Potent and Selective β3 Adrenergic Receptor Agonists

Antiviral activity and safety of aplaviroc, a CCR5 antagonist, in combination with lopinavir/ritonavir in HIV‐infected, therapy‐naïve patients: results of the EPIC study (CCR100136)

PhRMA CPCDC Initiative on Predictive Models of Human Pharmacokinetics, Part 1: Goals, Properties of the Phrma Dataset, and Comparison with Literature Datasets

Use of “N-in-one” Dosing to Create an in Vivo Pharmacokinetics Database for use in Developing Structure—Pharmacokinetic Relationships

Pharmacokinetics of hepatitis C virus NS5A inhibitor JNJ-56914845 (GSK2336805) in subjects with hepatic impairment

Evaluation of the Drug Interaction Potential of Aplaviroc, a Novel Human Immunodeficiency Virus Entry Inhibitor, Using a Modified Cooperstown 5 + 1 Cocktail

Steady-state brain concentrations of antihistamines in rats: interplay of membrane permeability, P-glycoprotein efflux and plasma protein binding

Monitoring liver safety in drug development: The GSK experience

The ABCG2 C421A polymorphism does not affect oral nitrofurantoin pharmacokinetics in healthy Chinese male subjects

Semicarbazone-based inhibitors of cathepsin K, are they prodrugs for aldehyde inhibitors?

Suchergebnisse filtern